Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits

Heart Rhythm. 2012 Dec;9(12):2051-8. doi: 10.1016/j.hrthm.2012.08.029. Epub 2012 Aug 28.

Abstract

Background: Ranolazine exhibits a synergistic effect in combination with class III drugs to suppress atrial fibrillation.

Objective: To investigate whether a combination therapy affects repolarization and provokes ventricular tachyarrhythmias (VT) in a sensitive model of proarrhythmia.

Methods: Thirty-seven rabbits were assigned to 3 groups and fed with amiodarone (50 mg/kg/d; n = 10) or dronedarone (50 mg/kg/d; n = 10) over a period of 6 weeks. A third group was used as control (n = 17). After obtaining baseline data in Langendorff-perfused control hearts, sotalol (100 μM) was administered in this group. Thereafter, ranolazine (10 μM) was additionally infused on top of amiodarone, dronedarone, or sotalol.

Results: Chronic treatment with amiodarone or dronedarone as well as sotalol significantly increased action potential duration at 90% repolarization (APD(90)). Additional treatment with ranolazine further increased APD(90) in amiodarone- and dronedarone-pretreated hearts but not in sotalol-treated hearts. Ranolazine increased postrepolarization refractoriness as compared with amiodarone or dronedarone alone owing to a marked effect on the refractory period. In contrast to amiodarone and dronedarone, acute application of sotalol increased dispersion of repolarization (P < .05). Additional treatment with ranolazine did not further increase spatial or temporal dispersion. After lowering extracellular [K(+)] in bradycardic hearts, no proarrhythmia occurred in amiodarone- or dronedarone-treated hearts whereas 11 of 17 sotalol-treated hearts showed early afterdepolarizations and subsequent polymorphic VT. Additional treatment with ranolazine reduced the number of VT episodes in sotalol-treated hearts and did not cause proarrhythmia in combination with amiodarone or dronedarone.

Conclusions: Application of ranolazine on top of class III drugs does not cause proarrhythmia despite a marked effect on ventricular repolarization. The effect of ranolazine on the repolarization reserve is associated with the lack of effect on early afterdepolarizations and dispersion of repolarization.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetanilides
  • Action Potentials / drug effects
  • Animals
  • Anti-Arrhythmia Agents
  • Disease Models, Animal
  • Electrocardiography / drug effects*
  • Female
  • Heart Conduction System / drug effects*
  • Heart Conduction System / physiopathology
  • Heart Ventricles / drug effects
  • Heart Ventricles / physiopathology*
  • Piperazines
  • Rabbits
  • Ranolazine
  • Tachycardia, Ventricular / drug therapy*
  • Tachycardia, Ventricular / physiopathology

Substances

  • Acetanilides
  • Anti-Arrhythmia Agents
  • Piperazines
  • Ranolazine